Canaccord Genuity Maintains Buy on Health Catalyst, Raises Price Target to $3

Benzinga · 2d ago
Canaccord Genuity analyst Richard Close maintains Health Catalyst (NASDAQ:HCAT) with a Buy and raises the price target from $2 to $3.